Neumirna Therapeutics
PrivateLast Round
Grant
Jun 12, 2025
Total Funding Raised
$23.13M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Neumirna Therapeutics is a biotechnology company that develops miRNA-based therapies targeting the root causes of neurological diseases such as epilepsy and Parkinson's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neumirna Therapeutics Comparables
Compare Neumirna Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SoVarGen Co., Ltd. | 84% | |
| Atalanta Therapeutics | 80% | |
| Aerska | 79% |
Neumirna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 12, 2025 | ||||
| Series A | Jan 8, 2025 | ||||
| Grant | Jun 12, 2024 | ||||
| Grant | Feb 29, 2024 | ||||
| Grant | Dec 15, 2023 | ||||
Grant | Aug 1, 2023 |
Neumirna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Grant |
| Innovestor | Series A, Seed |
| CURE Epilepsy | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Angelini Ventures | Series A |
| Sunstone Life Science Ventures | Seed |
| Invivo Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Open roles increased to 5, 2.1x the trailing average.
- Aug 31, 2026
Open roles increased to 5, representing 28% of headcount.
Recent news
Latest coverage and updates
- hiresSep 22, 2026
Neumirna hires Disa.
- hiresSep 22, 2026
Neumirna hires Disa Tehler as Head of RNA Therapeutics.
Neumirna Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Neumirna Therapeutics's valuation, stock price, and market status.
Is Neumirna Therapeutics a public or private company?
Neumirna Therapeutics is a private company.
What is the current stock price of Neumirna Therapeutics?
Neumirna Therapeutics is a private company, so its shares have no public market price. Caplight tracks Neumirna Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neumirna Therapeutics worth (valuation)?
Valuation information for Neumirna Therapeutics is not publicly available.
Can I buy Neumirna Therapeutics stock?
Neumirna Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neumirna Therapeutics's last funding round?
Neumirna Therapeutics's most recent funding round was Grant on June 12, 2025.
Who are the main investors in Neumirna Therapeutics?
Key investors in Neumirna Therapeutics include Innovation Fund Denmark, Angelini Ventures, Invivo Partners.
Will Neumirna Therapeutics IPO soon?
No public IPO plans have been announced for Neumirna Therapeutics.
How can I track Neumirna Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Neumirna Therapeutics's shares on secondary markets.